课题基金 / 基金详情

BIODEGRADABLE MICROSPHERES FOR CANCER IMMUNOTHERAPY

BIODEGRADABLE MICROSPHERES FOR CANCER IMMUNOTHERAPY
用于癌症免疫治疗的可生物降解微球
批准号:
6294467
负责人:
NEJAT K EGILMEZ
金额:
$9.99万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-08-01 至 2002-07-31

项目摘要

项目成果

NEJAT K EGILMEZ的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: A novel technology for the local and sustained delivery of immunostimulatory molecules to the tumor environment for cancer immunotherapy is evaluated. The ability of biodegradable polymer micro spheres loaded with murine Interleukin- 12 to promote the regression of established tumors and distant metastatic lesions is investigated in a syngeneic murine tumor model. The feasibility of this new sustained delivery system has ahead been established by demonstrating that different cytokines can be loaded into and released from the micro spheres in a biologically active form both in vitro and in vivo. Our objective here is to test our patent-protected cytokine-loaded micro spheres for their ability to deliver cytokines to established tumors and thereby eliminate tumors and provoke an antitumor immunity. In Aim 1, intralesional injections of IL-12- loaded micro spheres are employed to induce the suppression and/or regression of established primary tumors with the concomitant development of protective antitumor immunity. In Aim 2, the protocols that are found to be effective in Aim 1 are tested for their ability to promote the suppression of established lung metastases in a clinically relevant spontaneous metastasis model. The results from these Phase I studies are expected to establish whether cytokine-loaded micro spheres represent a simpler, more versatile and clinically feasible alternative to gene-modified tumor cell vaccines for adjuvant cytokine immunotherapy of cancer. PROPOSED COMMERCIAL APPLICATION: If proven effective, our tumor vaccination approach involving cytokine-loaded microspheres will provide a simple and universally applicable alternative to cumbersome and very expensive cytokine gene therapy strategies that are currently being tested in human clinical trials. This treatment has the potential to become a widely utilized adjuvant therapy to current standard treatments for cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Inflammation and Pathogenesis Training Program
  • 批准号:
    9753922
  • 项目类别:
  • 资助金额:
    $13.98万
  • 财政年份:
    2018
  • 负责人:
    NEJAT K EGILMEZ
  • 依托单位:
Oral Immune Modulatory Adjuvants for Treatment of Colorectal Carcinoma
Oral Immune Modulatory Adjuvants for Treatment of Colorectal Carcinoma
Integrating Innate & Adaptive Immunity in Cancer Therapy
  • 批准号:
    6725612
  • 项目类别:
  • 资助金额:
    $28.29万
  • 财政年份:
    2004
  • 负责人:
    NEJAT K EGILMEZ
  • 依托单位: